JP2022504236A5 - - Google Patents
Info
- Publication number
- JP2022504236A5 JP2022504236A5 JP2021518561A JP2021518561A JP2022504236A5 JP 2022504236 A5 JP2022504236 A5 JP 2022504236A5 JP 2021518561 A JP2021518561 A JP 2021518561A JP 2021518561 A JP2021518561 A JP 2021518561A JP 2022504236 A5 JP2022504236 A5 JP 2022504236A5
- Authority
- JP
- Japan
- Prior art keywords
- indazole
- piperidine
- phenyl
- carboxamide
- crystalline form
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862740872P | 2018-10-03 | 2018-10-03 | |
| US62/740,872 | 2018-10-03 | ||
| PCT/US2019/054534 WO2020072797A1 (en) | 2018-10-03 | 2019-10-03 | Niraparib salts |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022504236A JP2022504236A (ja) | 2022-01-13 |
| JP2022504236A5 true JP2022504236A5 (https=) | 2022-11-04 |
| JP7472115B2 JP7472115B2 (ja) | 2024-04-22 |
Family
ID=68345029
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021518561A Active JP7472115B2 (ja) | 2018-10-03 | 2019-10-03 | ニラパリブ塩 |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP3860981B1 (https=) |
| JP (1) | JP7472115B2 (https=) |
| KR (1) | KR20210071022A (https=) |
| CN (2) | CN113166071B (https=) |
| ES (1) | ES2967517T3 (https=) |
| TW (2) | TW202513550A (https=) |
| WO (1) | WO2020072797A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI905184B (zh) | 2020-05-08 | 2025-11-21 | 比利時商健生藥品公司 | 用醋酸阿比特龍和尼拉帕尼之組合治療前列腺癌 |
| JP2024525881A (ja) | 2021-07-19 | 2024-07-12 | ヤンセン ファーマシューティカ エヌ．ベー． | ニラパリブ（ｎｉｒａｐａｒｉｂ）による転移性去勢抵抗性前立腺癌の治療 |
| CN121311226A (zh) | 2023-05-17 | 2026-01-09 | 特沙诺有限公司 | 聚adp核糖聚合酶(parp)抑制剂在治疗癌症中的新用途 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE640616A (https=) | 1962-12-19 | |||
| US3492397A (en) | 1967-04-07 | 1970-01-27 | Warner Lambert Pharmaceutical | Sustained release dosage in the pellet form and process thereof |
| US4060598A (en) | 1967-06-28 | 1977-11-29 | Boehringer Mannheim G.M.B.H. | Tablets coated with aqueous resin dispersions |
| US3538214A (en) | 1969-04-22 | 1970-11-03 | Merck & Co Inc | Controlled release medicinal tablets |
| US4173626A (en) | 1978-12-11 | 1979-11-06 | Merck & Co., Inc. | Sustained release indomethacin |
| KR101653548B1 (ko) * | 2008-01-08 | 2016-09-02 | 머크 샤프 앤드 돔 리미티드 | 2-｛4-［（3ｓ）-피페리딘-3-일］페닐｝-2ｈ-인다졸-7-카복스아미드의 약제학적으로 허용되는 염 |
| EP2928473B1 (en) | 2012-12-07 | 2017-06-28 | Merck Sharp & Dohme Corp. | Regioselective n-2 arylation of indazoles |
| SMT202100065T1 (it) | 2013-05-02 | 2021-03-15 | Anaptysbio Inc | Anticorpi diretti contro la proteina della morte programmata (pd-1) |
| MA41463A (fr) | 2015-02-03 | 2017-12-12 | Anaptysbio Inc | Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3) |
| FI3277321T3 (fi) | 2015-04-01 | 2024-10-31 | Anaptysbio Inc | T-soluimmunoglobuliinia ja musiiniproteiini 3:a (tim-3) vastaan suunnattuja vasta-aineita |
| SG11201811564QA (en) | 2016-06-29 | 2019-01-30 | Tesaro Inc | Methods of treating ovarian cancer |
| MX2019005116A (es) | 2016-11-01 | 2019-11-12 | Anaptysbio Inc | Anticuerpos dirigidos contra la proteina de inmunoglobulina de linfocitos t y de mucina 3 (tim-3). |
| JP2019533458A (ja) | 2016-11-01 | 2019-11-21 | アナプティスバイオ インコーポレイティッド | プログラム死１（ｐｄ−１）に対する抗体 |
| CN108201537A (zh) * | 2016-12-16 | 2018-06-26 | 苏州苏融生物医药有限公司 | 一种尼拉帕尼缓控释药物组合物及其用途 |
| WO2018122168A1 (en) * | 2016-12-29 | 2018-07-05 | Bayer Pharma Aktiengesellschaft | Combinations of bub1 kinase and parp inhibitors |
| AU2018206481B2 (en) | 2017-01-09 | 2025-02-27 | Tesaro, Inc. | Methods of treating cancer with anti-PD-1 antibodies |
| WO2018129553A1 (en) | 2017-01-09 | 2018-07-12 | Tesaro, Inc. | Methods of treating cancer with anti-tim-3 antibodies |
| CN108203404A (zh) * | 2018-03-02 | 2018-06-26 | 上海博邦医药科技有限公司 | (r)-3-苯基哌啶或/和(s)-3-苯基哌啶以及尼拉帕尼的手性中间体的合成方法 |
-
2019
- 2019-10-03 CN CN201980078366.1A patent/CN113166071B/zh active Active
- 2019-10-03 TW TW113130597A patent/TW202513550A/zh unknown
- 2019-10-03 EP EP19794786.4A patent/EP3860981B1/en active Active
- 2019-10-03 KR KR1020217012838A patent/KR20210071022A/ko active Pending
- 2019-10-03 ES ES19794786T patent/ES2967517T3/es active Active
- 2019-10-03 WO PCT/US2019/054534 patent/WO2020072797A1/en not_active Ceased
- 2019-10-03 CN CN202411070879.7A patent/CN118994103A/zh active Pending
- 2019-10-03 TW TW108135909A patent/TWI853841B/zh active
- 2019-10-03 JP JP2021518561A patent/JP7472115B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022504236A5 (https=) | ||
| JP2020537657A5 (https=) | ||
| JP2021512117A5 (https=) | ||
| JP2019524883A5 (https=) | ||
| CN110573500A (zh) | N-(氮杂芳基)环内酰胺-1-甲酰胺衍生物及其制备方法和应用 | |
| JP2011529054A5 (https=) | ||
| RU2017115925A (ru) | Сокристаллы модуляторов регулятора трансмембранной проводимости при кистозном фиброзе | |
| JP2012516344A5 (https=) | ||
| JP2007091758A5 (https=) | ||
| JP2006527256A5 (https=) | ||
| JP2009537498A5 (https=) | ||
| JP2011527333A5 (https=) | ||
| JP2010514807A5 (https=) | ||
| JP2014530818A5 (https=) | ||
| CN110770233A (zh) | 稠合双环类化合物及其在药物中的应用 | |
| RU2019121700A (ru) | Твердые формы апалутамида | |
| JP2015510916A5 (https=) | ||
| CN108289890A (zh) | 含有2-{4-[n-(5,6-二苯基吡嗪-2-基)-n-异丙基氨基]丁氧基}-n-(甲磺酰基)乙酰胺的医药组合物 | |
| JP2022504228A5 (https=) | ||
| JP2019529460A5 (https=) | ||
| JP2013536243A5 (https=) | ||
| JP2016530238A5 (https=) | ||
| JP2013523623A5 (https=) | ||
| US12226381B2 (en) | Composition of fused tricyclic gamma-amino acid derivatives and the preparation thereof | |
| RU2016116789A (ru) | Комбинация энзалутамида и афурезертиба для лечения рака |